Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.

Published

Journal Article

BACKGROUND: Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most cryptogenic strokes are considered to be embolic and of undetermined source. An earlier randomized trial showed that rivaroxaban is no more effective than aspirin in preventing recurrent stroke after a presumed embolic stroke from an undetermined source. Whether dabigatran would be effective in preventing recurrent strokes after this type of stroke was unclear. METHODS: We conducted a multicenter, randomized, double-blind trial of dabigatran at a dose of 150 mg or 110 mg twice daily as compared with aspirin at a dose of 100 mg once daily in patients who had had an embolic stroke of undetermined source. The primary outcome was recurrent stroke. The primary safety outcome was major bleeding. RESULTS: A total of 5390 patients were enrolled at 564 sites and were randomly assigned to receive dabigatran (2695 patients) or aspirin (2695 patients). During a median follow-up of 19 months, recurrent strokes occurred in 177 patients (6.6%) in the dabigatran group (4.1% per year) and in 207 patients (7.7%) in the aspirin group (4.8% per year) (hazard ratio, 0.85; 95% confidence interval [CI], 0.69 to 1.03; P = 0.10). Ischemic strokes occurred in 172 patients (4.0% per year) and 203 patients (4.7% per year), respectively (hazard ratio, 0.84; 95% CI, 0.68 to 1.03). Major bleeding occurred in 77 patients (1.7% per year) in the dabigatran group and in 64 patients (1.4% per year) in the aspirin group (hazard ratio, 1.19; 95% CI, 0.85 to 1.66). Clinically relevant nonmajor bleeding occurred in 70 patients (1.6% per year) and 41 patients (0.9% per year), respectively. CONCLUSIONS: In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in preventing recurrent stroke. The incidence of major bleeding was not greater in the dabigatran group than in the aspirin group, but there were more clinically relevant nonmajor bleeding events in the dabigatran group. (Funded by Boehringer Ingelheim; RE-SPECT ESUS ClinicalTrials.gov number, NCT02239120.).

Full Text

Duke Authors

Cited Authors

  • Diener, H-C; Sacco, RL; Easton, JD; Granger, CB; Bernstein, RA; Uchiyama, S; Kreuzer, J; Cronin, L; Cotton, D; Grauer, C; Brueckmann, M; Chernyatina, M; Donnan, G; Ferro, JM; Grond, M; Kallmünzer, B; Krupinski, J; Lee, B-C; Lemmens, R; Masjuan, J; Odinak, M; Saver, JL; Schellinger, PD; Toni, D; Toyoda, K; RE-SPECT ESUS Steering Committee and Investigators,

Published Date

  • May 16, 2019

Published In

Volume / Issue

  • 380 / 20

Start / End Page

  • 1906 - 1917

PubMed ID

  • 31091372

Pubmed Central ID

  • 31091372

Electronic International Standard Serial Number (EISSN)

  • 1533-4406

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1813959

Language

  • eng

Conference Location

  • United States